This rate is lower than those reported by some other authors (7,6–8%) [7,8,30], but these previous studies only included patients with precocious epilepsy, while the current study included patients undergoing MECP2 screening, but with any type of epilepsy regardless of the age of onset. This evidence concerns the gene MECP2 and epilepsy.